United Therapeutics (UTHR)
Health Care · Rare disease / pulmonary hypertension pharmaceuticals
United Therapeutics is a rare disease specialist dominating pulmonary hypertension treatment through multiple treprostinil delivery formats while pursuing organ manufacturing innovation as a public benefit corporation.
What United Therapeutics does
United Therapeutics develops and commercializes therapies for serious rare diseases with unmet medical needs, with a primary focus on pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company's revenue is dominated by treprostinil-based therapies available in multiple delivery formats—including inhalation powder (Tyvaso DPI), nebulized inhalation solution (Nebulized Tyvaso), subcutaneous/intravenous injection (Remodulin), and oral tablets (Orenitram)—along with the phosphodiesterase-5 inhibitor Adcirca. The company also markets Unituxin, a monoclonal antibody for high-risk neuroblastoma, and operates as a public benefit corporation with a stated mission to advance organ manufacturing technologies alongside pharmaceutical innovation.
Themes: ["Pulmonary arterial hypertension (PAH) treatment","Pulmonary hypertension associated with interstitial lung disease (PH-ILD)","Treprostinil and prostacyclin pathway therapies","Rare disease / orphan drugs","Oncology (neuroblastoma immunotherapy)","Organ transplantation and regenerative medicine","Multiple delivery mechanisms for pulmonary drugs"]
Fundamentals
- Price$549.66 as of 2026-07-09 close
- Market cap$23.7B as of 2026-07-09
- 1-year return+88.3% as of 2026-07-09 close
- P/E18.44 as of 2026-07-09
- Net margin+40.6% as of 2026-07-09
- Gross margin+86.6% as of 2026-07-09
- ROE+19.2% as of 2026-07-09
- Debt / equity0.00 as of 2026-07-09
- Revenue growth (YoY)+5.9% as of 2026-07-09
- Revenue CAGR (3y)+18.0% SEC XBRL
- Beta0.56 as of 2026-07-09
Key risks (from latest filing)
["Heavy revenue concentration in treprostinil-based therapies; a material decrease in sales or prescribing patterns for Tyvaso DPI, Nebulized Tyvaso, Remodulin, or Orenitram would significantly harm operations","Generic competition and patent expiration risk; generic versions of treprostinil products have already negatively impacted revenues and additional generics could further erode market share","Clinical trial and regulatory approval uncertainty; failure to demonstrate safety and efficacy in development programs or delays in FDA approval could prevent commercialization of new products or indications and materially increase development costs"]
Competitors & peers
- Gilead Sciences (GILD) — endothelin pathway and nitric oxide pathway PAH therapies
- Actelion/Johnson & Johnson (JNJ) — endothelin receptor antagonists for PAH
- Bayer (BAYN) — riociguat and other PAH/pulmonary hypertension therapies
- Altisource (generic treprostinil manufacturers)
- Liquidia Technologies (LIQ) — Yupelri inhalation technology competitor
Fundamentals: Finnhub, as of 2026-07-09. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.